EXECUTIVE EMPLOYMENT AGREEMENT
Exhibit 10.1
EXECUTIVE EMPLOYMENT AGREEMENT
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is between Rocket Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and ▇▇▇▇▇ ▇▇▇▇▇▇▇ (“Executive”), and is dated as of July 7, 2025 (the “Effective Date”). Each of the Company and Executive are sometimes referred to in this Agreement individually as a “Party” and together as the “Parties.”
WHEREAS, the Company and Executive wish for Executive to be employed by the Company on the terms and conditions set forth in this Agreement as of the Effective Date.
NOW, THEREFORE, in consideration of the mutual promises, terms, covenants and conditions set forth in this Agreement and the performance of each, the Parties, intending to be legally bound, hereby agree as follows:
1
accordance with the Company’s normal performance review practices. Effective as of the date of any change to Executive’s Base Salary, the Base Salary as so changed will be considered the new Base Salary for all purposes of this Agreement.
2
shall forfeit all right, interest and entitlement to, any such Incentive Bonus payment for such fiscal year.
(30) days of its receipt of a written notice from Executive describing the applicable circumstances (which notice must be provided by Executive within ninety (90) days of Executive’s knowledge of the applicable circumstances), of one or more of the following: (1) any material, adverse change in Executive’s duties, responsibilities, authority, title or reporting structure; (2) a material reduction in Executive’s base salary or bonus opportunity; or (3) a geographical relocation of Executive’s principal office location by more than twenty-five (25) miles.
$2,500,000 (the “Total Value”) and will be apportioned among the two Grants as set in this Section 2(d) using the closing price on the day of the grant. One of the two Grants, representing 50% of the Total Value, will be in the form of an option to purchase shares of the Company’s common stock, and the other of the two Grants, representing 50% of the Total Value, will be in the form of restricted stock units settled in shares of the Company’s common stock. The Grants will be subject to the terms and conditions of the Plan and the grant agreements issued by the Company thereunder.
3
4
5
6
The items described under Sections 3(a)(i) through 3(a)(iii) are referred to collectively as the “Accrued Amounts.”
7
outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (c) the sale of all of the stock of the Company to an unrelated person, entity or group thereof acting in concert, or (d) any other transaction in which the owners of the Company’s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company. Notwithstanding any other provision contained herein, if Executive’s employment under this Agreement is terminated by Executive for Good Reason or by the Company without Cause (other than on account of Executive’s death or Disability), in each case within 12 months following a Change in Control, Executive will be entitled to receive, subject to Executive’s execution and non-revocation of a Release:
8
the Company and the performance of Executive’s duties under this Agreement will not violate or be a breach of any agreement with a former employer, client or any other person or entity.
9
benefit, and (b) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year will not affect the expenses eligible for reimbursement, or in- kind benefits to be provided, in any other taxable year.
10
the Company’s General Counsel (or equivalent position within the Company) or the Company’s advisers, as the Company may reasonably request, to assist it in any matter regarding the Company and its subsidiaries, including giving truthful testimony in any litigation, potential litigation or any internal investigation or administrative, regulatory, judicial or quasi-judicial proceedings involving the Company or its subsidiaries, with respect to which Executive has knowledge, experience or information. Executive acknowledges that this could involve, but is not limited to, responding to or defending any regulatory or legal process, providing information in relation to any such process, preparing witness statements and giving evidence in person on behalf of the Company. The Company will work with Executive to ensure that such cooperation does not unduly burden Executive, work in good faith to accommodate Executive’s other commitments and reimburse any reasonable expenses incurred by Executive, including reasonable attorneys’ fees and costs, as a consequence of complying with Executive’s obligations under this Section 10, provided that such expenses are approved in advance by the Company.
To the Company:
Rocket Pharmaceuticals, Inc. ▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Cranbury, NJ 08512 Attn: General Counsel
Telephone Number: (▇▇▇) ▇▇▇-▇▇▇▇
E-Mail: ▇▇▇▇▇▇▇@▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ To Executive:
▇▇▇▇▇ ▇▇▇▇▇▇▇ at the contact information on file with the Company
Either Party may, by notice given in accordance with this Section 12, specify a new address for notices under this Agreement.
11
12
13
[Signature Page Follows]
14
IN WITNESS WHEREOF, the Parties have executed this Executive Employment Agreement as of the day and year first above written.
Company:
By: Name:▇▇▇▇▇▇ ▇▇▇▇
Title: CEO
Executive:
▇▇▇▇▇ ▇▇▇▇▇▇▇
